

Serum Lipid Profile in Pediatric Bronchial Asthma

Thesis

Submitted for the Partial Fulfillment of Master degree in **Pediatrics**

Presented By

Hend Hamdy El Sayed Ali

MBBCh. Ain Shams University, (2012)

Under the supervision of

Prof. Dr. Tharwat Ezzat Deraz

Professor of Pediatrics Faculty of Medicine Ain Shams University

Dr. Mahitab Morsy Hussein

Lecturer of Pediatrics Faculty of medicine Ain Shams University

Dr. Hoda Ahmed AbdElSattar

Lecturer of Clinical Pathology Faculty of Medicine Ain Shams University

Faculty of Medicine - Ain Shams University
2019



سورة البقرة الآية: ٣٢

Acknowledgment

First and foremost, I feel always indebted to ALIAH, the Most Kind and Most Merciful.

I'd like to express my respectful thanks and profound gratitude to **Prof. Dr./ Thanwat** Ezzat **Deraz**, Professor of Pediatrics - Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.

I am also delighted to express my deepest gratitude and thanks to **Dr. Mahitab Morsy Hussein**, Lecturer of Pediatrics, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.

I am deeply thankful to **Dr. 76oda Ahmed AbdElSattar**, Lecturer of Clincial Pathology, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Hend Hamdy El Sayed Ali

List of Contents

Title	Page No.
List of Tables	i
List of Figures	vi
List of Abbreviations	vii
Introduction	1
Aim of the Work	5
Review of Literature	
■ Bronchial Asthma	6
Dyslipidemia	42
Patients and Methods	74
Results	85
Discussion	111
Summary	131
Conclusion	139
Recommendations	140
References	141
Arabic Summary	

List of Tables

Table No.	Title	Page	No.
Table (1):	GINA assessment of asthma contradults, adolescents and children years	6–11	32
Table (2):	Acceptable, Borderline-high, and Plasma Lipid and Lipoprotein Range Children and Adolescents according to 2011 Expert Panel on Integ Guidelines for Cardiovascular Health Risk Reduction in Children	High es for o the rated n and	
Table (3):	Adolescents	and	59
Table (4):	step II Diets	anges ng to rated n and	67
m 11 (5)	Risk Reduction in Children Adolescents		75
Table (5):	Stepwise approach to asthma treatme adults and children older than 5 according to GINA guidelines	years	78
Table (6):	American Thoracic Society Grades severity of abnormal FEV1 of predresults	s for licted	80
Table (7):	Descriptive statistics for age in both and control.	cases	
Table (8):	Descriptive statistics for sex in both and control.	cases	
Table (9):	Descriptive statistics for socioecon class (SEC) in both cases and co according to Fahmy and ELSher	nomic ontrol	86

Table No.	Title	Page	No.
Table (10):	Descriptive statistics for exposur second hand passive smoking in cases and control.	both	86
Table (11):	Descriptive statistics for history of forms of atopy (allergic rhinitis & allergy) among cases	other food	
Table (12):	Descriptive statistics for degre severity of asthma among cases		87
Table (13):	Descriptive statistics for level of co		87
Table (14):	Descriptive statistics for exacerbathrough the last month among cases		88
Table (15):	Descriptive statistics for use of diffasthma controller medications a cases.	erent mong	
Table (16):	Descriptive statistics for FEV1 garding pulmonary function test among according to American Thoracic Sources of severity.	ing in cases	
Table (17):	Descriptive statistics for s cholesterol level, serum triglyceride serum LDL level, serum HDL among cases according to the 2011 E Panel on Integrated Guidelines Cardiovascular Health and	erum level, level xpert for Risk	
Table (18):	Reduction in Children and Adolescen Statistical comparison between case control as regard body weight, heigh	s and	89
Table (19):	body mass index. Statistical comparison between case control as regard serum cholesterol serum LDL level, serum HDL serum triglycerides.	s and level, level,	

Table No.	Title Pag	je No.
Table (20):	Correlation between serum cholestero level and (age, duration of disease, bod weight, Body mass index (BMI) pulmonary function test parameters and	y),
Table (21):	serum total Ig E). Correlation between serum triglyceride and (age, duration of disease, bod weight, BMI, pulmonary function tesparameters, serum total IgE, serum level of cholesterol, serum level of LDL and	92 s y et el
	serum level of HDL)	93
Table (22):	Correlation between serum low densit ; lipoprotein and (age, duration of disease, body weight, Body mass index pulmonary function test parameters serum total IgE and serum level of cholesterol)	of x, s,
Table (23):	Correlation between serum high density lipoprotein and (age, duration, bod weight, Body mass index, pulmonar function test parameters, serum total IgE, serum level of cholesterol and serum level of LDL)	y y ıl n
Table (24):	Mean serum level of cholesterol, LDI HDL and triglycerides among males and females in our cases group	., d
Table (25):	Effect of exposure to second hand passiv smoking on mean serum level of cholesterol, LDL, HDL and triglycerides.	e of
Table (26):	Effect of degree of seveity of asthma or mean serum level of cholesterol, LDI HDL and triglycerides	n 4,

Table No.	Title Page	No.
Table (27):	Effect of level of control of asthma on	
	mean serum level of cholesterol, LDL,	
T 11 (20)	HDL and triglycerides.	100
Table (28):	Effect of exacerbations through the last	
	month on mean serum level of cholesterol,	101
Table (29):	LDL, HDL and triglycerides Effect of coexistence of allergic rhinitis on	101
1 abie (29):	mean serum level of cholesterol, LDL,	
	HDL and triglycerides	102
Table (30):	Effect of using inhaled corticosteroids on	102
14610 (60).	mean serum level of cholesterol, LDL,	
	HDL and triglycerides	103
Table (31):	Effect of using inhaled	
	corticosteroids/long acting beta 2 agonist	
	on mean serum level of cholesterol, LDL,	
	HDL and triglycerides	104
Table (32):	Comparison between asthmatics with	
	dyslipidemia and asthmatics without	
	dyslipidemia as regard the following	
	[duration of asthma, total serum IgE,	
	pulmonary function test parameters (FEV1, FVC, FEV/FVC ratio, MMEF 25-	
	(FEV1, FVC, FEV/FVC ratio, WIMEF 25-75)]	105
Table (33):	Comparison between asthmatics with	100
14610 (66).	dyslipidemia and asthmatics without	
	dyslipidemia as regard FEV1 grading	106
Table (34):	Comparison between asthmatics with	
	dyslipidemia and asthmatics without	
	dyslipidemia as regard sex.	107
Table (35):	Comparison between asthmatics with	
	dyslipidemia and asthmatics without	
	dyslipidemia as regard exposure to	
	second hand passive smoking	108

Table No.	Title	Page No.
Table (36):	Comparison between asthmatics dyslipidemia and asthmatics wi dyslipidemia as regard level of cont	thout
Table (37):	asthma. Comparison between asthmatics dyslipidemia and asthmatics widyslipidemia as regard degree of several degree degre	with thout
	of asthma	110

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Pathogenesis of asthma	18
Figure (2):	Multiple mechanisms of air obstruction in asthma	
Figure (3):	Bronchial airway remodeling in seasthma	
Figure (4):	Stepwise approach to control sympt and minimize future Risk in add adolescents and children 6–11 years old	ults,
Figure (5):	Hypothetical model of pro-inflamma role of serum cholesterol in enhance expression of asthma	nced
Figure (6):	Diagnostic and management algorithm pediatric dyslipidemia	

List of Abbreviations

Full term Abb. ABPAAllergic bronchopulmonary aspergillosis ACQAsthma control questionnaire $ACT.....Asthma\ control\ test$ AIDSAcquired immunodeficiency syndrome Apo-E.....Apolipoprotein ASMAirway smooth muscle BMI.....Body mass index CDCCenter for Disease Control and Prevention CHILDCardiovascular Health Integrated Lifestyle CK......Creatinine kinase COPD......Chronic obstructive pulmonary disease CVDCardiovascular diseases DMDiabetes mellitus ED.....Emergency department FACET.....Formoterol and Corticosteroids Establishing Therapy FDA.....Food and Drug administration FENO.....Fractional exhales nitric oxide FEV/FVC ratio .. Forced expiratory volume / forced vital capacity FEV1.....Forced expiratory volume in 1 second FhXFamily history FVC.....Forced viatal capacity GEMCASThe German Metabolic and Cardiovascular Risk Project GI.....GastrointestinalGINA.....Global Initiative for Asthma HDLHigh density lipoprotein HDL-CHigh density lipoprotein cholesterol

List of Abbreviations (Cont...)

Abb.	Full term
HIV	Human immunodeficiency virus
HMG-CoA	The 3 –hydroxy-methyl-glutaryl-coenzyme
	Ipratropium bromide
ICS	$Inhaled\ corticosteroid$
ICS/LABA	Inhaled corticosteroid and long acting beta 2 agonist
<i>IgE</i>	Immunoglobulin~E
_	Immunoglobulin~G
<i>IL6</i>	Interleukin 6
ISAAC	International Study of Asthma and allergies in Childhood
<i>LABA</i>	Lomg cting beta 2 agonist
LDL	Low density lipoprotein
LDL-C	Low density lipoprotein cholesterol
LTRA	Leukotriene receptor antagonist
Med	Medium dose
MMEF25-75	Maximum mid expiratory flow
<i>N</i>	Number
NAEPP	National Asthma Education and Prevention Program
NCEP	The National Cholesterol E ducation Program
NHANES	The National Health and Nutrition Examination Survey
NHLBI	The National Heart, Lung and Blood Institue
NO	Nitric oxide
OCS	Oral corticosteroids
P	Propability of error
	Peak expiratory flow
<i>Ppb</i>	Parts per billion
<i>RFs</i>	Risk factors

List of Abbreviations (Cont...)

Abb.	Full term
<i>RSV</i>	Respiratory syncytial virus
<i>SABA</i>	Short acting beta 2 agonist
<i>SAMA</i>	Short-acting muscarinic antagonist
SCG	Sodium cromoglycate
<i>SD</i>	Standard deviation
SEC	Socioeconomic class
<i>SLIT</i>	Sublingual immunotherapy
<i>TB</i>	Tuberculosis
<i>TC</i>	Total cholesterol
<i>TG</i>	Triglycerides
Th1	T helper 1
Th2	T helper 2
<i>TNF</i>	Tumor necrosis factor
TRAP	Traffic-related air pollution
<i>TSH</i>	Thyroid stimulating hormone
<i>US</i>	United States
<i>VLDL</i>	Very low density lipoprotein
<i>WHO</i>	World health organization

Introduction

affecting children. Globally, about 300 million people have asthma, and current trends suggest that an additional 100 million people may be living with asthma by 2025. The World Health Organization (WHO) estimates about 250 000 deaths from asthma every year, mainly in low and middle-income countries. The fast rate of urbanization has been linked to the increase in the burden of asthma. The International Study of Asthma and Allergies reported that asthma prevalence among children was increasing in Africa and has contributed to the burden of disease through its effects on quality of life. Inpatient admissions and purchase of medications account for most of the direct costs on government, while loss of productivity, due to absenteeism from work and school, are responsible for most of the indirect costs (Adelove et al., 2013).

In Egypt, several studies have shown a significantly higher prevalence of asthma. For example, prevalence rate of asthma was 7.7% among school children in the Nile delta region (*Zedan et al., 2009*) and it was 46.1% among school children in Al Maasara and Al Maadi region (*Al Dhduh et al., 2015*), while among 11–15-yr-old schoolchildren in Cairo the overall prevalence of wheezing was 14.7% and of physician-diagnosed asthma was 9.4%(*Georgy et al., 2006*) and among



school children aged 6-12 years in Assuit district it was 7.2% (Hassan et al., 2017).

Global Initiative for Asthma (GINA) 2011, has defined asthma as a chronic inflammatory disorder of the airways. The chronic airway inflammation is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. The chronic inflammatory state in asthma is triggered and maintained by environmental factors. There are many host related factors that add to this inflammation and increase the occurrence of asthma. One such proinflammatory host factor that has gained interest among researchers in recent years is cholesterol level. It is well established hypercholesterolemia is associated with enhanced expression of proinflammatory mechanisms leading to increased levels of proinflammatory cytokines cellular adhesion molecules and inflammation sensitive plasma proteins (Ramarju et al., 2013).

Dyslipidemia, a condition involving elevated serum triglyceride (TG), elevated serum low density lipoprotein cholesterol (LDL-C), and/or low serum high density lipoprotein cholesterol (HDL-C), has become a health problem of growing concern (Gowdy et al., 2013).

A number of pathophysiologic mechanisms could explain the direct association found between childhood asthma and high serum triglycerides, this association is consistent with